Palatin Technologies Stock Price, News & Analysis (NYSEAMERICAN:PTN) $2.22 +0.22 (+11.00%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$1.95▼$2.2250-Day Range$1.97▼$2.9152-Week Range$1.43▼$5.00Volume134,517 shsAverage Volume62,675 shsMarket Capitalization$30.50 millionP/E RatioN/ADividend YieldN/APrice Target$70.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesOwnershipSEC FilingsShort Interest Palatin Technologies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside3,053.2% Upside$70.00 Price TargetShort InterestHealthy4.87% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.67 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPalatin Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $70.00, Palatin Technologies has a forecasted upside of 3,053.2% from its current price of $2.22.Amount of Analyst CoveragePalatin Technologies has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.87% of the float of Palatin Technologies has been sold short.Short Interest Ratio / Days to CoverPalatin Technologies has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Palatin Technologies has recently decreased by 10.77%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPalatin Technologies does not currently pay a dividend.Dividend GrowthPalatin Technologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PTN. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 8 people have searched for PTN on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows12 people have added Palatin Technologies to their MarketBeat watchlist in the last 30 days. This is an increase of 1,100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Palatin Technologies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.70% of the stock of Palatin Technologies is held by insiders.Percentage Held by InstitutionsOnly 7.86% of the stock of Palatin Technologies is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Palatin Technologies is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palatin Technologies is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Palatin Technologies Stock (NYSEAMERICAN:PTN)Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.Read More PTN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTN Stock News HeadlinesNovember 16, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN), Palatin Technologies (PTN) and ProKidney (PROK)November 15, 2023 | finance.yahoo.comPalatin Technologies, Inc. (AMEX:PTN) Q1 2024 Earnings Call TranscriptDecember 3, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 15, 2023 | markets.businessinsider.comPalatin Technologies Receives Buy Rating: F1Q24 Results Surpass Expectations and MELODY-1 Trial Shows Promising ProgressNovember 15, 2023 | finance.yahoo.comQ1 2024 Palatin Technologies Inc Earnings CallNovember 14, 2023 | markets.businessinsider.comPalatin Technologies Inc. Q1 Loss decreases, but misses estimatesNovember 14, 2023 | finance.yahoo.comPalatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdateNovember 13, 2023 | finance.yahoo.comKronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue EstimatesDecember 3, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 9, 2023 | finance.yahoo.comPalatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023October 25, 2023 | msn.comImmunityBio, Palatin Technologies among healthcare moversOctober 25, 2023 | investing.comEarnings call: Palatin reports strong growth and optimistic future plans in Q4 2023 earnings callOctober 24, 2023 | finance.yahoo.comPalatin Announces Closing of $5 Million Registered Direct OfferingOctober 23, 2023 | marketwatch.comPalatin Technologies Shares Drop 13% After Private Placement PricesOctober 23, 2023 | finance.yahoo.comPalatin Announces $5 Million Registered Direct OfferingOctober 19, 2023 | finanznachrichten.deFinancialnewsmedia.com: Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related DisordersOctober 18, 2023 | markets.businessinsider.comPalatin: GLP-1 & MC4R Agonist Co-administration Data Shows Increased Weight LossOctober 18, 2023 | finance.yahoo.comPalatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese PatientsOctober 16, 2023 | finance.yahoo.comPalatin Presents Data at the United European Gastroenterology Week 2023 Conference On PL8177 Ulcerative Colitis TreatmentOctober 13, 2023 | finance.yahoo.comPalatin Receives Notice of Non-Compliance from NYSE AmericanOctober 3, 2023 | finance.yahoo.comPalatin Technologies, Inc. (AMEX:PTN) Q4 2023 Earnings Call TranscriptSeptember 30, 2023 | markets.businessinsider.comPalatin Technologies Earns Buy Rating Amid Strong Performance and Promising Clinical DevelopmentsSeptember 29, 2023 | msn.comPalatin Technologies: Falls as quarterly profit misses estimateSeptember 29, 2023 | markets.businessinsider.comBuy Rating for Palatin Technologies: Promising Clinical Programs and High Upside PotentialSeptember 29, 2023 | finance.yahoo.comQ4 2023 Palatin Technologies Inc Earnings CallSeptember 28, 2023 | marketwatch.comPalatin Technologies Shares Fall 10% After Wider-Than-Expected 4Q LossSeptember 28, 2023 | finance.yahoo.comPalatin Reports Fourth Quarter and Fiscal Year Ended 2023 Financial Results and Provides Corporate UpdateSee More Headlines Receive PTN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palatin Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today12/02/2023Next Earnings (Estimated)2/13/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:PTN Previous SymbolNYSE:PTN CUSIPN/A CIK911216 Webwww.palatin.com Phone(609) 495-2200Fax609-495-2202Employees34Year FoundedN/APrice Target and Rating Average Stock Price Target$70.00 High Stock Price Target$70.00 Low Stock Price Target$70.00 Potential Upside/Downside+3,053.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,540,000.00 Net Margins-413.38% Pretax Margin-490.15% Return on Equity-583.06% Return on Assets-142.33% Debt Debt-to-Equity Ratio0.34 Current Ratio0.72 Quick Ratio0.60 Sales & Book Value Annual Sales$4.85 million Price / Sales6.29 Cash FlowN/A Price / Cash FlowN/A Book Value($0.36) per share Price / Book-6.17Miscellaneous Outstanding Shares13,740,000Free Float12,679,000Market Cap$30.50 million OptionableNot Optionable Beta0.91 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Carl Spana Ph.D. (Age 61)Co-Founder, President, CEO & Director Comp: $979kMr. Stephen T. Wills CPA (Age 66)MST, CFO, COO, Executive VP, Treasurer & Secretary Comp: $910.55kBurns McClellanVice President of Investor RelationsMr. Stephen A. Slusher Esq.Chief Legal OfficerDr. Michael B. Raizman M.D.Chief Medical OfficerMr. James E. Hattersley (Age 63)Senior Vice President of Business Development Mr. John Dodd Ph.D.Senior Vice President of Preclinical DevelopmentMr. Robert JordanSenior Vice President of Program OperationsMore ExecutivesKey CompetitorsPharmaxisOTCMKTS:PXSLYRegulus TherapeuticsNASDAQ:RGLSIntelGenx TechnologiesOTCMKTS:IGXTMolecular TemplatesNASDAQ:MTEMAmarillo BiosciencesOTCMKTS:AMARView All CompetitorsInsiders & InstitutionsUBS Group AGBought 28,792 shares on 11/9/2023Ownership: 0.241%Alan W DuntonSold 200 sharesTotal: $594.00 ($2.97/share)View All Institutional Transactions PTN Stock Analysis - Frequently Asked Questions Should I buy or sell Palatin Technologies stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" PTN shares. View PTN analyst ratings or view top-rated stocks. What is Palatin Technologies' stock price target for 2024? 1 equities research analysts have issued twelve-month target prices for Palatin Technologies' stock. Their PTN share price targets range from $70.00 to $70.00. On average, they anticipate the company's share price to reach $70.00 in the next year. This suggests a possible upside of 3,053.2% from the stock's current price. View analysts price targets for PTN or view top-rated stocks among Wall Street analysts. How have PTN shares performed in 2023? Palatin Technologies' stock was trading at $3.87 at the start of the year. Since then, PTN shares have decreased by 42.6% and is now trading at $2.22. View the best growth stocks for 2023 here. Are investors shorting Palatin Technologies? Palatin Technologies saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 748,300 shares, an increase of 40.1% from the October 15th total of 534,300 shares. Based on an average daily volume of 116,900 shares, the days-to-cover ratio is presently 6.4 days. Currently, 5.5% of the company's shares are sold short. View Palatin Technologies' Short Interest. When is Palatin Technologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024. View our PTN earnings forecast. How were Palatin Technologies' earnings last quarter? Palatin Technologies, Inc. (NYSEAMERICAN:PTN) issued its earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.07. The biopharmaceutical company had revenue of $2.11 million for the quarter, compared to analysts' expectations of $1.87 million. Palatin Technologies had a negative trailing twelve-month return on equity of 583.06% and a negative net margin of 413.38%. During the same quarter last year, the company posted ($0.86) EPS. When did Palatin Technologies' stock split? Palatin Technologies shares reverse split on the morning of Wednesday, August 31st 2022. The 1-25 reverse split was announced on Wednesday, August 31st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 31st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Palatin Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Trevena (TRVN), Alliqua Biomedical (ALQA), Catalyst Pharmaceuticals (CPRX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), TherapeuticsMD (TXMD) and Actinium Pharmaceuticals (ATNM). Who are Palatin Technologies' major shareholders? Palatin Technologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include UBS Group AG (0.24%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Palatin Technologies? Shares of PTN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSEAMERICAN:PTN) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palatin Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.